Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296164 · ClinicalTrials.gov registry record
Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
A clinical trial, sponsored by Helsinn Therapeutics (U.S.).
- Completed
- Registry status
- 300
- Enrollment target
NCT02296164 is a clinical trial that has completed, run by Helsinn Therapeutics (U.S.). The registered enrollment target is 300 participants.
The verdict
NCT02296164 has completed, sponsored by Helsinn Therapeutics (U.S.).
- COMPLETED
- Registry status
- 300 participants
- Enrollment target
Study Summary
The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL) who are receiving therapy with Valchlor. Patients will be followed prospectively for a maximum of 2 years from the date of signed informed consent (enrollment) until end of study. Continuation in the study is not contingent on continuation of Valchlor.
Interventions
- DRUG Valchlor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2014-11-12 |
| Est. Completion | 2018-10-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296164
The ClinicalTrials.gov registry entry for NCT02296164 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helsinn Therapeutics (U.S.), which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valchlor is the first listed.
NCT02296164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02296164 about?
NCT02296164 is a clinical study titled "Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma". The Valchlor PROVe study is a multi-center, prospective, observational, US-based drug study that longitudinally follows patients with Mycosis Fungoides Cutaneous T-cell Lymphoma (MF-CTCL) who are receiving therapy with Valchlor. Patients will be followed prospectively for a maximum of 2 years from t...
What is the current status of trial NCT02296164?
This trial is currently completed. The enrollment target is 300 participants. The study started on 2014-11-12. Estimated completion is 2018-10-17.
What interventions are being tested in trial NCT02296164?
The interventions under investigation include: Valchlor (DRUG).
Who is sponsoring clinical trial NCT02296164?
This trial is sponsored by Helsinn Therapeutics (U.S.), which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.